^
Association details:
| Biomarker: | ROR1 expression |
|---|---|
| Cancer: | Hematological Malignancies |
| Drug: | CS5001 (DNA replication inhibitor, ROR1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract LBA008: CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable β-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies
Published date:
12/01/2021
Excerpt:
CS5001 exhibited prominent antitumor activity in both Jeko-1 and MDA-MB-231 xenograft models in a dose-dependent manner. In Jeko-1, complete regression (CR) was observed after a single administration of CS5001 at 1mg/kg (approximate 1/5th the maximum tolerated dose (MTD) in mice)...CS5001 exhibited potent and selective cytotoxicity to a variety of ROR1-expressing cell lines and showed remarkable in vivo antitumor activity. ROR1 cytometric density predicts sensitivity to CS5001 in vitro. CS5001 is a promising therapeutic candidate for ROR1-expressing hematological and solid malignancies with precision medicine potential.
DOI:
10.1158/1535-7163.TARG-21-LBA008
